Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: lipocalins - Pieris Pharmaceuticals

Drug Profile

Research programme: lipocalins - Pieris Pharmaceuticals

Alternative Names: Anticalin®; Anticalins®; CardioClean; DigiCal; OncoCal I; Pieries-110; PRS-010; PRS-030; PRS-055; PRS-056; PRS-070; PRS-090; PRS-110; PRS-130; PRS-190

Latest Information Update: 18 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pieris
  • Developer AbbVie; Pieris; Pieris Pharmaceuticals; Zydus Cadila
  • Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Lipocalins
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 23 inhibitors; Interleukin-17 inhibitors; Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Eye disorders
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 28 Jan 2020 No recent reports of development identified for preclinical development in Cancer in Germany
  • 25 Jan 2018 Lipocalin variants (Pieries-110) is still in preclinical development for Cancer in Germany (Zydus Cadila pipeline, January 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top